Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Annals of Hematology

Open Access 25-09-2024 | Sorafenib | Case Report

15-year remission in refractory FLT3-mutated AML attained by sorafenib

Authors: Christoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, Robert Zeiser, Justus Duyster, Jürgen Finke, Michael Lübbert

Published in: Annals of Hematology

Login to get access

Excerpt

The outcome of most AML patients relapsing after allogeneic hematopoietic cell transplantation (HCT) remains dismal. The FLT3 internal tandem duplication (ITD) mutation provides a rational therapeutic target for treatment with tyrosine kinase inhibitors (TKIs) in the post-HCT setting. Sorafenib is widely used as maintenance therapy and induces durable remissions in patients relapsing after HCT in combination with donor-lymphocyte infusions (DLIs) via sorafenib-induced upregulation of IL-15 in FLT3-ITD-mutated blasts [1, 2]. We report a remarkable course of a patient who is in continued molecular remission following 7.5 years of sorafenib treatment (combined with a total of 13 DLIs) and 7.5 years without any specific anti-leukemic therapy. …
Appendix
Available only for authorised users
Literature
1.
Mathew NR et al (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282–291CrossRefPubMedPubMedCentral
2.
Metzelder SK et al (2017) Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer Oxf Engl 1990 86:233–239
3.
4.
Burchert A et al (2020) Sorafenib Maintenance after allogeneic hematopoietic stem cell transplantation for Acute myeloid leukemia with FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol off J Am Soc Clin Oncol 38:2993–3002CrossRef
5.
Xuan L et al (2023) Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10:e600–e611CrossRefPubMed
Metadata
Title
15-year remission in refractory FLT3-mutated AML attained by sorafenib
Authors
Christoph Rummelt
Dietmar Pfeifer
Ralph Wäsch
Robert Zeiser
Justus Duyster
Jürgen Finke
Michael Lübbert
Publication date
25-09-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-06012-3

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits